Genome Medicine Publishes Baylor Team’s Article on the Contribution of Copy Number Variants and Runs of Homozygosity in Molecular Diagnosis of Patients

Copy number variant and runs of homozygosity detection by microarrays enabled more precise molecular diagnoses in 11,020 clinical exome cases

Avinash V. Dharmadhikari†; Rajarshi Ghosh†; Bo Yuan; Pengfei Liu; Hongzheng Dai; Sami Al Masri; Jennifer Scull; Jennifer E. Posey; Allen H. Jiang; Weimin He; Francesco Vetrini; Alicia A. Braxton; Patricia Ward; Theodore Chiang; Chunjing Qu; Shen Gu; Chad A. Shaw; Janice L. Smith; Seema Lalani; Pawel Stankiewicz; Sau-Wai Cheung; Carlos A. Bacino; Ankita Patel; Amy M. Breman; Xia Wang; Linyan Meng; Rui Xiao; Fan Xia; Donna Muzny; Richard A. Gibbs; Arthur L. Beaudet; Christine M. Eng; James R. Lupski; Yaping Yang and Weimin Bi

†Contributed equally

Published: May 17, 2019



Exome sequencing (ES) has been successfully applied in clinical detection of single nucleotide variants (SNVs) and small indels. However, identification of copy number variants (CNVs) using ES data remains challenging. The purpose of this study is to understand the contribution of CNVs and copy neutral runs of homozygosity (ROH) in molecular diagnosis of patients referred for ES.


In a cohort of 11,020 consecutive ES patients, an Illumina SNP array analysis interrogating mostly coding SNPs was performed as a quality control (QC) measurement and for CNV/ROH detection. Among these patients, clinical chromosomal microarray analysis (CMA) was performed at Baylor Genetics (BG) on 3229 patients, either before, concurrently, or after ES. We retrospectively analyzed the findings from CMA and the QC array.


The QC array can detect ~ 70% of pathogenic/likely pathogenic CNVs (PCNVs) detectable by CMA. Out of the 11,020 ES cases, the QC array identified PCNVs in 327 patients and uniparental disomy (UPD) disorder-related ROH in 10 patients. The overall PCNV/UPD detection rate was 5.9% in the 3229 ES patients who also had CMA at BG; PCNV/UPD detection rate was higher in concurrent ES and CMA than in ES with prior CMA (7.2% vs 4.6%). The PCNVs/UPD contributed to the molecular diagnoses in 17.4% (189/1089) of molecularly diagnosed ES cases with CMA and were estimated to contribute in 10.6% of all molecularly diagnosed ES cases. Dual diagnoses with both PCNVs and SNVs were detected in 38 patients. PCNVs affecting single recessive disorder genes in a compound heterozygous state with SNVs were detected in 4 patients, and homozygous deletions (mostly exonic deletions) were detected in 17 patients. A higher PCNV detection rate was observed for patients with syndromic phenotypes and/or cardiovascular abnormalities.


Our clinical genomics study demonstrates that detection of PCNV/UPD through the QC array or CMA increases ES diagnostic rate, provides more precise molecular diagnosis for dominant as well as recessive traits, and enables more complete genetic diagnoses in patients with dual or multiple molecular diagnoses. Concurrent ES and CMA using an array with exonic coverage for disease genes enables most effective detection of both CNVs and SNVs and therefore is recommended especially in time-sensitive clinical situations.

Genome Medicine (2019)


For more information on the products and/or services mentioned…

Previous Post
Clinical Exome Reanalyses Lead to New Molecular Diagnoses
Next Post
Test Updates // Oncology // FISH Panel Probes (October 2019)